Borderline Personality Disorder Polypharmacy: Where to Start Deprescribing
A single father on four psychotropics accumulated over fifteen years for BPD reports daytime sedation that's starting to interfere with parenting. The disagreement isn't whether to deprescribe -- it's which drug to taper first, and how many changes can safely happen at once.
D.K., a 41-year-old single father raising two teenage daughters, has been in psychiatric care for borderline personality disorder since he was twenty-four, but the psychiatrist who managed nearly all of that history retired six months ago, and today is his first full visit with the new prescriber taking over his file. He arrives with a specific, practical complaint rather than a diagnostic one: he has started falling asleep some afternoons before his daughters get home from school, twice missed helping the younger one with a math assignment she needed same-day, and is quietly worried about driving them anywhere in the evening.
His chart shows four psychotropic medications accumulated over fifteen years, each added at a different point for a different reason that made sense at the time: divalproex sodium, started at twenty-six for what his prior chart calls “mood swings” without any documented history of discrete manic or hypomanic episodes; quetiapine, added at low dose eight years ago for sleep and evening agitation; sertraline, added five years ago after a depressive episode that has not recurred; and clonazepam, started three years ago as an as-needed anxiety medication that became a standing twice-daily dose within the first year. He has been clinically stable on this combination — no hospitalizations, no self-harm — for the past three years, which is precisely what makes today's conversation harder than a simple review of what isn't working.
That accumulation pattern — four agents, no single one clearly load-bearing on its own, added sequentially rather than chosen together — is not unusual for this diagnosis; a 2015 UK survey by Paton and colleagues found psychotropic polypharmacy was the norm rather than the exception in patients carrying this diagnosis, despite national guidance explicitly recommending against it. What makes D.K.'s case a genuine decision rather than an obvious one is that stability and daytime sedation are not opposites here — they may be the same regimen producing both effects at once, and untangling which drug is responsible for which requires a plan, not just an instinct to cut back.
Medication reconciliation, first visit with new prescriber
Fifteen years of sequential additions and no clear ongoing target for at least two of these four medications is exactly the picture national guidance warns about. Divalproex was started for “mood swings” with nothing in the record suggesting a bipolar-spectrum diagnosis that would actually justify a mood stabilizer. Clonazepam has been a standing dose for two years with no re-evaluation of whether the anxiety it was started for still exists in the same form. His own complaint today — falling asleep on the afternoons that matter to his daughters — is a real harm, not a side note, and it argues for a full, honest review of this whole regimen now rather than continuing by default because nothing has gone acutely wrong.
I agree the regimen needs review — I'm not defending four drugs with no plan behind them. But “full review” can't mean touching all four agents at once.
He's been stable for three years on this exact combination. If we change divalproex, quetiapine, and clonazepam in the same window and something shifts — mood, sleep, anxiety — we won't know which change caused it, which means we can't safely reverse course if we need to. Clonazepam specifically carries real physiologic dependence risk after this many years of continuous use; stopping it abruptly, or even tapering it alongside other changes without its own dedicated slow-taper protocol, risks withdrawal seizures, not just rebound anxiety. NICE's own guidance for this diagnosis explicitly calls for reviewing and discontinuing ineffective treatment — it doesn't say do it all in one visit. One drug at a time, in a defined order, is how this actually gets done safely.
I'd pick the order using his own complaint rather than chronological order or a general principle. Quetiapine and clonazepam are both sedating; between the two, clonazepam is the one carrying its own independent physiologic risk from continued use, on top of having the thinner original justification. I'd start there — a slow, scheduled taper over several months, watched carefully for both withdrawal symptoms and any return of the anxiety it was meant to treat — before touching divalproex or sertraline at all. If daytime sedation improves substantially once clonazepam is out of the picture, that may answer the quetiapine question on its own, without a second simultaneous taper.
Agreed: begin a slow, scheduled clonazepam taper only, with defined check-ins to watch for both withdrawal symptoms and any return of the anxiety it was originally meant to treat. Divalproex, quetiapine, and sertraline continue unchanged for now, explicitly deferred rather than cleared.
The quetiapine question may answer itself; a separate review of divalproex's original justification still follows, on its own timeline, once the clonazepam taper is complete.
Quetiapine becomes the next agent reviewed, using the same one-at-a-time approach — not a signal to revisit the whole regimen at once.
Not agreed: how urgently the divalproex question needs answering given its unclear original indication. The Attending Psychiatrist would prefer to schedule that review now, several months out; the Psychiatric Pharmacist would rather let the clonazepam taper finish cleanly first and decide the next step from there, without a review already on the calendar.